Amendments to the Claims:

This listing of claims shall replace all prior versions and listing of the claims in this application:

1. (Currently amended) An expandable medical device for delivery of a beneficial agent, the device comprising:

a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter, the substantially cylindrical device comprising a plurality of deformable members and non-deformable members;

a first plurality of through openings formed in the substantially cylindrical device containing a first beneficial agent for delivery to tissue, wherein the first plurality of through openings are positioned on first and second ends of the cylindrical device;

a second plurality of through openings formed in the substantially cylindrical device containing a second beneficial agent for delivery to tissue, wherein the second plurality of through openings are positioned on a central portion of the cylindrical device between the first and second ends, and wherein the second beneficial agent is different than the first beneficial agent; and

wherein the first plurality of through openings containing first beneficial agent and the second plurality of through openings containing second beneficial agent are positioned on the non-deformable members.

2. (Currently amended) The device of Claim 1, wherein the second beneficial agent includes a drug which is the same as a drug included in the ~~firsts~~ first beneficial agent in a different concentration.

3. (Original) The device of Claim 1, wherein the second beneficial agent includes a drug which is the same as a drug included in the first beneficial agent with a different eluting profile.

4. (Original) The device of Claim 1, wherein the first and second beneficial agents comprise different drugs.

5. (Previously presented) The device of Claim 1, wherein the first and second beneficial agents comprise different forms of the same drug.

6. (Currently amended) The device of Claim 1, wherein the first plurality of through openings contain a first beneficial agent having a higher concentration than the second beneficial agent contained in the second plurality of through openings.

7. (Original) The device of Claim 1, further comprising a third beneficial agent coated on the substantially cylindrical device.

8. (Original) The device of Claim 1, wherein the first beneficial agent is paclitaxel, or an analogue or derivative thereof.

9. (Original) The device of Claim 1, wherein the first beneficial agent is rapamycin, or an analogue or derivative thereof.

10. (Previously presented) A tissue supporting device comprising:

a tissue supporting device body configured to support a bodily lumen, the tissue supporting device comprising deformable and non-deformable members;

a first beneficial agent contained in first through openings in the tissue supporting device for delivery to tissue, wherein the first through openings are positioned on first and second ends of the device body;

a second beneficial agent contained in second through openings in the tissue supporting device for delivery to tissue, wherein the second through openings are positioned on a central portion of the device body between the first and second ends; and

wherein the first through openings containing first beneficial agent and the second through openings containing second beneficial agent are positioned in the non-deformable members.

11. (Original) The device of Claim 10, wherein the second beneficial agent includes a drug which is the same as a drug included in the first beneficial agent in a different concentration.

12. (Original) The device of Claim 11, wherein the first beneficial agent is paclitaxel, or an analogue or derivative thereof.

13. (Original) The device of Claim 11, wherein the first beneficial agent is rapamycin, or an analogue or derivative thereof.

14. (Original) The device of Claim 10, wherein the second beneficial agent includes a drug which is the same as a drug included in the first beneficial agent with a different eluting profile.

15. (Original) The device of Claim 10, wherein the first and second beneficial agents comprise different drugs.

16. (Previously presented) The device of Claim 10, wherein the first and second beneficial agents comprise different forms of the same drug.

17. (Currently amended) An expandable medical device for delivery of a beneficial agent, the device comprising:

a device body which is expandable from an initial configuration to an expanded configuration defining a cylinder having end holes at opposite ends of the device;

a side hole in the device body between the opposite ends and having a center axis substantially perpendicular to a longitudinal axis of the device body and configured to accommodate a bifurcation in a lumen;

a first plurality of through openings formed in the device body containing a first beneficial agent for delivery to tissue at the expanded configuration, wherein the first plurality of through openings are formed in an area surrounding the side hole; and

a second plurality of through openings formed in the body device in an area away from the side hole.

18. (Currently amended) The device of Claim 17, wherein the device body includes a plurality of interconnected struts and the first and second plurality of through openings are formed in the struts.

19. (Currently amended) The device of Claim 17, wherein first beneficial agent includes a higher concentration of an anti-restenosis agent than a second beneficial agent in the second plurality of through openings.

20. (Previously presented) A method of reducing restenosis in a body passageway, the method comprising:

positioning a tissue supporting device comprising deformable and non-deformable members in a body passageway to support the tissue, the tissue supporting device containing a first and a second beneficial agent in through openings positioned in the non-deformable members in the device; and

delivering the first beneficial agent to tissue at locations adjacent ends of the tissue supporting device and the second beneficial agent to tissue between the ends of the device to reduce restenosis.

21. (Original) The method of Claim 20, wherein the two different beneficial agents comprise the same drug in different concentrations.

22. (Original) The method of Claim 20, wherein the second beneficial agent includes a drug which is the same as a drug included in the first beneficial agent with a different eluting profile.

23. (Original) The method of Claim 20, wherein the two different beneficial agents comprise different drugs.

24. (Original) The method of Claim 20, wherein the two different beneficial agents comprise different forms of the same drug.

25. (Currently amended) An expandable medical device for delivery of a beneficial agent, the device comprising:

a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter, the substantially cylindrical device comprising deformable and non-deformable members;

a first plurality of through openings formed in the substantially cylindrical device containing the beneficial agent in a first concentration;

a second plurality of through openings formed in the substantially cylindrical device containing the beneficial agent in a second concentration, wherein the first and second plurality of through openings are arranged to deliver a uniform distribution of a drug to the tissue of a body passageway; and

wherein the first plurality of through openings and the second plurality of through openings are positioned in the non-deformable members.

26. (Currently amended) The device of Claim 25, wherein the substantially cylindrical device includes a plurality of interconnected struts and bridging elements, the first plurality of through openings are formed in the struts, and the second plurality of through openings are formed in the bridging elements.

27. (Currently amended) The device of Claim 25, wherein a volume of the first plurality of through openings per unit of surface area of the expanded device is greater than a volume of the second plurality of through openings per unit of surface area and the first concentration is less than the second concentration to achieve the uniform distribution of the drug.

28. (Currently amended) The device of Claim 25, wherein the first and second plurality of through openings are different sizes.

29. (Canceled)

30. (Canceled)

31. (Currently amended) The device of Claim 1, wherein the ~~plurality of~~ first and second plurality of through openings are laser cut through holes.

32. (Previously presented) The device of Claim 1, wherein the substantially cylindrical device is a stent.

33. (Currently amended) The device of Claim 10, wherein the ~~plurality of~~ first and second plurality of through openings are laser cut through holes.

34. (Previously presented) The device of Claim 10, wherein the tissue supporting device is a stent.

35. (Currently amended) The device of Claim 25, wherein the ~~plurality of~~ first and second plurality of through openings are laser cut through holes.

36. (Canceled)

37. (Canceled)

38. (Canceled)

39. (Canceled)

40. (Canceled)

41. (Currently amended) A tissue supporting device comprising:

a generally cylindrical tissue supporting device body configured to support a bodily lumen;

a plurality of first through openings in the tissue supporting device body, wherein the first through openings contain a first beneficial agent; and

a plurality of second through openings in the tissue supporting device body, wherein the second through openings contain a second beneficial agent;

wherein the tissue supporting device body comprises a plurality of deformable members and non-deformable members, the plurality of first and second through openings being positioned in the non-deformable members.

42. (Previously presented) The device of Claim 41, wherein the second beneficial agent includes a drug which is the same as a drug included in the first beneficial agent in a different concentration.

43. ((Previously presented) The device of Claim 41, wherein the second beneficial agent includes a drug which is the same as a drug included in the first beneficial agent with a different eluting profile.

44. (Previously presented) The device of Claim 41, wherein the first and second beneficial agents comprise different drugs.

45. (Previously presented) The device of Claim 41, wherein the first and second beneficial agents comprise different forms of the same drug.

46. (Currently amended) The device of Claim 41, wherein the plurality of first through openings contain a first beneficial agent having a higher concentration than the second beneficial agent contained in the plurality of second through openings.

47. (Previously presented) The device of Claim 41, further comprising a third beneficial agent coated on the substantially cylindrical device.

48. (Previously presented) The device of Claim 41, wherein the first beneficial agent is paclitaxel, or an analogue or derivative thereof.

49. (Previously presented) The device of Claim 41, wherein the first beneficial agent is rapamycin, or an analogue or derivative thereof.

50. (Previously presented) The device of Claim 41, wherein the plurality of first and second through openings are laser cut through holes.

51. (Previously presented) The device of Claim 41, wherein the plurality of first and second through openings have different shapes.

52. (Previously presented) The device of Claim 41, wherein the plurality of first and second through openings have different sizes.

53. (Canceled)